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Sir,
In the last 25 years, highly active antiretroviral therapy has been
continuously improving the life expectation and quality of
HIV-infected people. As new drugs were more effective and
adverse events less frequent and severe, HIV infection turned
into a chronic disease. Recently licensed drugs, such as
raltegravir and darunavir, are characterized by high efficacy
and tolerability. However, on 2 November 2011, updates to the
Isentress (raltegravir) package insert were approved by the FDA
to include a new warning, subsequent to the post-marketing
experience.1 Severe, potentially life-threatening and fatal skin
reactions have been reported during raltegravir treatment.
Several classes of antiretroviral drugs have been associated
with cutaneous adverse events, in particular non-nucleoside
reverse transcriptase inhibitors and protease inhibitors.2 Some of
these events may lead to treatment discontinuation; their early
detection is clinically relevant in order to prevent severe reactions.
In the literature, information about raltegravir and skin reac-
tions is still scanty. A recent paper3 stating the efficacy and
safety of raltegravir in association with etravirine and darunavir/
ritonavir reported one case of recurrent epidermal necrolysis
leading to raltegravir discontinuation, out of 100 multiexper-
ienced patients (1.0%). Antiretroviral drugs associated with
adverse cutaneous reactions were reviewed by Borra´s-Blasco
et al.,4 who reported that in Phase II and III studies raltegravir
was mainly associated with skin rash of mild to moderate inten-
sity, not leading to discontinuation. Long-term safety data from
clinical trials5 showed that rash frequency during raltegravir
treatment was higher compared with placebo, but lower in
comparison with efavirenz.
To add information on this issue, we report the results from
the SCOLTA (Surveillance COhort Long-term Toxicity Antiretrovir-
als) project. This is an online reporting system for adverse
reactions to antiretroviral drugs, designed by the CISAI (Coordi-
namento Italiano per lo Studio Allergia e Infezione da HIV;
Italian Coordination for the Study of Allergy and HIV Infection)
group. It originated as a pharmacovigilance system for newly
introduced drugs and as a sentinel scheme for unexpected or
late adverse reactions arising during any antiretroviral treat-
ment. It works through the internet site www.cisai.info and
currently involves 18 Italian infectious disease centres.
Cohorts of patients are established for each new drug as it
comes onto the market, and these patients are followed
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prospectively. Data collection and follow-up procedures for the
cohorts have been described previously.6 In 2006 we started to
collect information on patients taking raltegravir. Subjects were
followed up every 6 months, including information about blood
lipids, liver function and immunological examinations. Grade 3–
4 adverse events that occurred at any time were recorded; any
grade event leading to drug discontinuation was also reported.
As of January 2012, 469 patients on raltegravir treatment had
been enrolled in this study (67% males, mean age 46 years,
7.0% naive, 40% stage C); 448 (95.5%) had at least one
follow-up and the median observation time was 23 months.
Table 1 summarizes the main features of these patients.
Among these patients six skin adverse reactions were
reported (three cases of diffuse itching and three cases of cuta-
neous rash); two (one itching and one rash) led to drug discon-
tinuation, but none was life-threatening. Nine patients died
during the study, for reasons unrelated to skin adverse reactions.
In this sample there were 816 person-years of observation;
the incidence of adverse skin reactions was 0.73/100 person-
years (95% CI, 0.15–1.32). The frequency of drug discontinu-
ation related to skin reactions was 0.4%.
To our knowledge, at present this study includes the largest
series of patients treated with raltegravir and prospectively fol-
lowed aside from clinical trials. In conclusion, we found that
raltegravir-treated patients observed in a real-life setting
showed a low frequency of severe skin reactions.
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Table 1. Demographic and clinical baseline characteristics of 448
patients enrolled in the raltegravir cohort
N, mean or
median %, SD or IQR
Age (years) 45.8 9.2
Sex
male 300 67.0
female 148 33.0
HIV transmission category
IVDU 164 36.6
sexual 241 53.8
other or unknown 43 9.6
CDC stage
A 135 30.1
B 139 31.0
C 174 38.8
CD4 count (cells/mL)a
,200 126 28.4
200–499 199 44.9
≥500 118 26.6
HIV viral load at study entry ,50 copies/mL 175 39.1
HCV positive 173 38.6
Lipodystrophy 179 40.0
Previous antiretroviral therapy (years) 10.4 5.6
Concomitant treatment
NRTI alone 82 18.3
PI 312 69.6
NNRTI 74 16.5
other drugs 69 15.4
Total cholesterol (mg/dL) 187 59
HDL cholesterol (mg/dL) 42 15
Triglycerides (mg/dL) 153 108–233
Glucose (mg/dL) 94 31
Observation period (months) 23 13–30
Reason for discontinuation
death 9 2.0
virological failure 13 2.9
adverse events 15 3.3
STI 3 0.7
simplification 4 0.9
lost to follow-up 17 3.8
other 21 4.7
IVDU, intravenous drug use; HCV, hepatitis C virus; NRTI, nucleoside/
nucleotide reverse transcriptase inhibitor; PI, protease inhibitor; NNRTI,
non-nucleoside reverse transcriptase inhibitor; HDL, high density lipoprotein;
STI, structured treatment interruption.
aFive patients had missing information on CD4 count at enrolment.
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In HIV-infected patients, some
differential alterations of CD4 and CD8
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Sir,
We read with interest the recent manuscript by Me´ndez-Lagares
et al.1 describing significant alterations in T cell homeostasis in
patients on highly active antiretroviral therapy (HAART) showing
low-level CD4 T cell repopulation, despite long-lasting and
persistent viral replication control. In particular, notable reduc-
tions of circulating naive CD4 T cells with increased expression
of markers for activation, senescence and proliferation were
found in comparison with patients with satisfactory CD4 T cell
repopulation. These results agree with their proposed model of
immune impairment in patients with low-level CD4 T cell repopu-
lation,2 suggesting intrinsic thymus failure and specific features
of premature immune senescence.
Our laboratory is actively working on a custom eight-colour
flow-cytometry assay (BD LyoTube 8-color CD4 and CD8
bundle, BD Biosciences, San Jose, CA, USA), which is able to
analyse differentiation, activation and senescence in CD4
and CD8 T cells (CD4 Lyotube: CD95 FITC/CCR7 PE/CD3 PerCP-Cy
5.5/CD25 PE-Cy7/CD127 Alexa Fluor 647/CD45 APC-H7/CD4
AmCyan/CD45RA V450; clones DX2/150503/SK7/2A3/HIL-7R-M-
21/2D1/SK3/HI100, respectively; and CD8 Lyotube: CD38
FITC/CCR7 PE/CD3 PerCP-Cy 5.5/CD69 PE-Cy7/CD127 Alexa
Fluor 647/CD45 APC-H7/CD8 AmCyan/CD45RA V450; clones
HB7/150503/SK7/L78/HIL-7R-M-21/2D1/SK1/HI100, respect-
ively). Stained and lysed whole blood was analysed on an
FACS-Canto II flow cytometer using FACS-Diva v.6.1.3 software
(BD Biosciences). This test, performed on whole blood on a semi-
routine scale, proved useful to analyse T cell homeostasis in
HIV-infected persons in a protocol approved by the Institute’s
Ethics Committee. In particular, this approach allowed us to
verify that naive CD4 T cell frequency was lower in patients
unable to reach CD4 reconstitution than in HIV patients reaching
CD4 reconstitution [7.4% (IQR: 1.2–20.0) versus 33.1% (IQR:
27.9–43.9), P,0.0001],3 confirming the results of
Me´ndez-Lagares et al.1
In order to evaluate how HAART impacts on CD4 and CD8 T cell
homeostasis, residual samples from 10 untreated HIV-infected
persons were analysed by this assay before starting treatment
and after 6 months of treatment. After 6 months of treatment,
all patients fulfilled immune reconstitution criteria [CD4 cells/
mm3: 530 (IQR: 467–834)] and obtained viral load control
[plasma viral load: undetectable (,40 copies/mL)]. Thirty-two
seronegative healthy donors (HDs) were used as controls.
Table 1 summarizes the immunological parameters that are
found to be affected by HIV infection: these include CD95 expres-
sion on CD4 T cells, Treg frequency and CD8 activation markers.
Many of these factors are positively modulated by 6 months of
successful HAART, gradually approaching, but not reaching, the
level found in HDs: CD4+, CD4CM+CD95+, Treg, CD8EM+
CD127+ and CD8+CD69+. Others are completely restored, as
in HDs: CD8+CD38+, CD8EM+CD38+, CD8TEMRA+CD38+,
CD8TEMRA+CD127+ and CD8CM+CD69+. Notably, two CD8
T cell subsets (CD8CM+ and CD8TEMRA+) seem negatively
affected by HAART, increasing the difference with respect to
HDs. Finally, many immunological markers are not affected at
all by HAART (Table 1, last column). Thus, the short-term
control of HIV replication seems able to allow a reduction of
CD8 T cell activation and of CD4 apoptosis, but fails to completely
restore CD4 and CD8 T cell homeostasis.
Moreover, in order to ascertain if long-term HAART may be
effective in fully restoring CD4 and CD8 T cell homeostasis,
residual samples from 18 HIV-infected patients treated with
HAART for 7–10 years, with recovered CD4 counts [CD4 cells/
mm3: 910 (IQR: 685–1074)] and with a controlled viral load
[plasma viral load: undetectable (,40 copies/mL)], were also
analysed. Notably, many parameters that were not restored
after 6 months of HAART were found fully normalized after long-
term HAART. Nevertheless, as shown in Table 2, some markers
(CD4+CD95+, CD4CM+CD95+, CD8+, CD8NA+, CD8+CD127+,
CD8NA+CD127+ and CD8EM+CD127+) remained significantly
altered, despite long-term immunological and virological treat-
ment response. These observations suggest immune homeo-
stasis damage inflicted by HIV infection in the active
replication phase that cannot be recovered by (apparently)
successful HAART.
As markers of treatment efficacy, HIV-RNA plasma levels and
CD4 T cell count are routinely used; in particular, the CD4 count
itself plays a major role, since counts below the 200 cells/mm3
threshold have been associated with a worse prognosis, and
therefore has been adopted in international guidelines to guide
and evaluate antiretroviral treatment decisions.4 Despite its
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